Overview

Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus

Status:
Terminated

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The objectives of this study are to compare in nucleoside treatment-naïve subjects, the efficacy and safety of clevudine 30 mg once daily versus adefovir 10 mg once daily, each as monotherapy, for 48 weeks and 96 weeks.

Phase:

Phase 3

Details

Lead Sponsor:

Pharmasset

Treatments:

Adefovir
Adefovir dipivoxil
Clevudine